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Purpose: To assess clinical antimicrobial efficacy results obtained with besifloxacin ophthalmic 
suspension, 0.6%, administered three times a day (TID) for 5 days, integrated across three clinical 
trials of bacterial conjunctivitis and to investigate any microbiological eradication failures.
Methods: Clinical microbiological eradication data from three randomized, double-masked, 
parallel group studies of patients with bacterial conjunctivitis (two vehicle controlled; one active 
controlled with moxifloxacin ophthalmic solution, 0.5%) were integrated. All bacterial samples 
isolated at baseline above the species-specific threshold value were subjected to antimicrobial 
susceptibility testing. Samples isolated at subsequent visits were subjected to susceptibility test-
ing and pulsed-field gel electrophoresis (PFGE) to investigate the cause of eradication failures 
and the potential for drug resistance development.
Results: Visit 2 (day 4 or 5) and visit 3 (day 8) overall microbiological eradication rates were 
92.2% and 88.4% for besifloxacin ophthalmic suspension compared with 61.4% and 72.5% for 
vehicle and 91.6% and 85.7% for moxifloxacin ophthalmic solution. Visit 2 and visit 3 micro-
biological eradication rates for Gram-positive and Gram-negative isolates and for individual 
species were consistent with the overall eradication rates. The majority of observed eradication 
failures in any treatment group were due to the persistence of the pathogen isolated at baseline. 
Eradication failures in the besifloxacin treatment group were not associated with lower anti-
microbial susceptibility at baseline. PFGE data showed that the majority of bacterial strains in 
eyes with eradication failures were identical to the strain isolated at baseline; these eradication 
failures were not associated with a lower antimicrobial susceptibility at the follow-up visit.
Conclusion: Treatment with besifloxacin ophthalmic suspension, 0.6%, administered TID for 
5 days resulted in microbiological eradication rates that were $ 90% across the three clinical 
studies for the common pathogens of bacterial conjunctivitis. The few eradication failures 
were not due to fluoroquinolone resistance at baseline and/or resistance development during 
treatment.
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Introduction
Bacterial conjunctivitis is a common eye infection characterized by marked hyper-
emia or redness of the eye, and mild-to-moderate purulent conjunctival discharge.1 
Symptoms often include tearing, itching, and ocular irritation.1 The condition often 
presents suddenly in one eye and can readily spread to the other eye as a contagious 
disease.1,2 Although the disease is generally self-limited,3 treatment with a topical broad-
spectrum ocular anti-infective shortens the duration of the disease, reduces contagious 
spread, and enhances the eradication of causative organisms.1–4 Treatment of bacterial 
conjunctivitis is mostly empiric and based upon the likely causative   pathogens and 
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local antibiotic resistance patterns.5 Therefore, the choice 
of therapy should ensure good activity against both Gram-
positive and Gram-negative organisms.
Besivance® (besifloxacin ophthalmic suspension, 0.6%; 
Bausch & Lomb, Rochester, NY) was approved in 2009 by the 
United States Food and Drug Administration for the treatment 
of bacterial conjunctivitis. Besifloxacin is a novel 8-chloro-
fluoroquinolone with an N-1 cyclopropyl substituent. The 
amino azepinyl substituent at the C-7 position and the chlo-
rine at the C-8 position give besifloxacin a unique structure 
and activity profile.6 In vitro studies show besifloxacin to be 
highly active against both Gram-positive and Gram-negative 
bacteria, including multidrug-resistant strains,7 and to be rap-
idly bactericidal.8,9 The average maximum tear concentration 
(Cmax) of besifloxacin following instillation of a single drop 
of besifloxacin ophthalmic suspension, 0.6%, in healthy vol-
unteers is 610 ± 540 µg/g, while the total exposure (AUC0–24 
[area under the curve from 0–24 hours]) is 1232 µg*h/g.10 
The average maximum conjunctival tissue concentration is 
2.3 ± 1.42 µg/g.11 The broad-spectrum antibacterial activity 
and pharmacokinetic properties of besifloxacin are consis-
tent with observed effectiveness in bacterial conjunctivitis 
clinical trials.12–15
This paper reports on clinical microbial eradication rates 
obtained with besifloxacin ophthalmic suspension, 0.6%, 
integrated across three multicenter, randomized, controlled, 
double-masked clinical trials.16–18 These clinical trials, two 
vehicle controlled and one active controlled, were conducted 
to evaluate the safety and efficacy of besifloxacin ophthalmic 
suspension, 0.6%, compared with vehicle, or moxifloxacin 
ophthalmic solution, 0.5%, dosed topically three times daily 
(TID) for 5 days, in the treatment of bacterial conjunctivitis. 
The integrated analyses were undertaken to define how robust 
the microbiological eradication data observed with besifloxa-
cin ophthalmic suspension was across these three studies and 
to investigate the cause(s) of any eradication failures. The 
companion paper by Haas et al19 presents a detailed analysis 
of the distribution of baseline pathogens in these studies along 
with current antibacterial resistance profiles.
Methods
Studies
Microbiological data from three prospective, randomized, 
multicenter, double-masked clinical trials (two vehicle con-
trolled and one active controlled; ClinicalTrials.gov identi-
fiers: NCT00622908, NCT00347932, and NCT00348348) 
evaluating the clinical safety and efficacy of besifloxacin 
ophthalmic suspension, 0.6%, in the treatment of   bacterial 
conjunctivitis were integrated. All trial protocols were 
conducted in accordance with Good Clinical Practices, the 
International Conference on Harmonization guidelines, the 
Declaration of Helsinki, and the Health Insurance Portabil-
ity and Accountability Act guidelines. Individual study 
results, including clinical and safety findings, are reported 
elsewhere.16–18 The two vehicle-controlled studies16,17 were 
conducted at 35 and 58 sites, respectively, in the US, and 
enrolled 269 and 957 patients, respectively. The active-
controlled study was conducted at 73 sites in the US plus 
11 sites in Asia and enrolled 1167 patients.18
In all three studies, patients aged 1 year and older were 
eligible for participation if they had a clinical diagnosis of 
bacterial conjunctivitis as evidenced by grade 1 or greater 
purulent conjunctival discharge and bulbar conjunctival 
injection in at least one eye and had pinhole visual acuity of 
20/200 or better in both eyes. Female patients of childbearing 
potential were required to use a reliable contraceptive method 
and have a negative pregnancy test prior to enrolment. 
Patients were excluded if they: had a known hypersensitiv-
ity to fluoroquinolones, besifloxacin ophthalmic suspension, 
or any of the ingredients in the study medications; had used 
topical ophthalmic anti-inflammatory agents within 48 hours 
before or during the study or other topical ophthalmic solu-
tions (including tear substitutes) within 2 hours before or 
during the study; had used antibacterial medications within 
72 hours of study entry; or had suspected viral or allergic 
conjunctivitis, suspected iritis, a history of recurrent corneal 
erosion syndrome, or any active ulcerative keratitis.
Patients completed three study visits. At the first visit 
(day 1), patient’s eligibility was determined by: a clinical 
assessment of ocular signs and symptoms in both eyes; 
an eye examination that included pinhole visual acuity, 
biomicroscopy, and ophthalmoscopy; and culture of the 
infected eye(s). Cultures were taken from the cul-de-sac of 
the affected eye(s) prior to instillation of any medication, and 
samples were analyzed by a central laboratory for quantitative 
microbiology to enumerate and identify bacterial pathogens 
as well as to identify the presence of any co-infecting virus 
or yeast (details of the culturing methods are provided in 
the companion paper by Haas et al).19 The conjunctivitis 
was considered culture-confirmed if the bacterial colony 
count equaled or exceeded the threshold value for that spe-
cies on the Cagle list as modified by Leibowitz.20,21 Patients 
were instructed to administer one drop of study medication 
TID at approximately 6-hour intervals for 5 days. Clinical 
assessments performed at visit 1 were repeated at visit 2 (day 
4 [± 1]16 or day 5 [± 1]17,18 and visit 3 (day 8 or 9).16–18 The 
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primary efficacy endpoints included clinical resolution of 
conjunctivitis, defined as the absence of both ocular discharge 
and bulbar conjunctival injection, and microbiological eradi-
cation of the baseline bacterial infection in culture-confirmed 
study eyes. Microbiological eradication was defined as the 
absence of all ocular bacterial species that were present at or 
above the Cagle threshold at baseline (visit 1).
In vitro susceptibilities to besifloxacin and comparator 
antibacterial agents were determined for all bacterial isolates 
at or above the Cagle threshold at baseline (visit 1) and 
any subsequent visit(s) (visit 2 and/or visit 3) regardless of 
treatment group. Minimum inhibitory concentrations (MICs) 
were determined by broth microdilution according to the 
procedure recommended by the Clinical and Laboratory 
Standards Institute (CLSI),22,23 and resulting MIC values were 
interpreted according to the susceptibility criteria published 
by CLSI.24,25 Isolates from selected species were further 
characterized by their antimicrobial resistance phenotype as 
described in the companion paper by Haas et al.19
Integrated analyses
Because microbiological specimen collection was the same 
across the three studies, and laboratory analysis procedures 
were the same and also conducted at the same central labora-
tory across the three studies, microbiological results from all 
three studies were pooled for a comprehensive, integrated 
analysis. The proportions of individual species at or above 
threshold across the three studies were tabulated along with 
their in vitro susceptibilities and antimicrobial resistance 
phenotypes. Microbiological eradication rates for besifloxa-
cin ophthalmic suspension and comparator treatments were 
integrated by combining individual study data listings for 
each treatment group at each follow-up visit. In all three 
studies, missing data and discontinued patients were imputed 
as microbiological eradication failures. While only one eye 
per patient (study eye) was considered for the primary effi-
cacy endpoints in the original study analyses,16–18 both eyes 
could contribute samples to the integrated microbiological 
analysis if both eyes had signs and symptoms of bacterial 
conjunctivitis and the pathogenic organism in the nonstudy 
eye was different from the organism in the study eye. In addi-
tion, more than one species from each eye were included if 
each species met the Cagle criteria.20
Eradication failures
While clinical antimicrobial efficacy was initially char-
acterized using a 4-point outcome scale in each study, 
where 0 = eradication, 1 = reduction, 2 = persistence, 
and 3 =   proliferation (definitions provided in Table 1), 
  microbiological eradication was evaluated on a binary scale 
(eradication/noneradication) for the primary efficacy end-
point reported in each study. Data listings for the noneradi-
cation categories (eg, reduction, persistence, proliferation) 
from each study were combined and used to characterize 
microbiological eradication failures in the integrated analysis. 
The initial characterization into noneradication categories 
was based on the assumption that when the infecting spe-
cies was present at follow-up, it was the same strain as that 
present at baseline.
To further investigate the potential cause(s) of observed 
microbiological eradication failures, several analyses were 
conducted. First, to determine if microbiological eradication 
failures were associated with antimicrobial susceptibility 
at baseline, the numbers of isolates eradicated/noneradi-
cated at visit 2 and visit 3 with besifloxacin ophthalmic 
suspension and moxifloxacin ophthalmic solution were 
plotted as a function of the besifloxacin or moxifloxacin 
MICs, respectively, for the pathogen at baseline. Sec-
ondly, to determine the contribution of new infections as 
opposed to persistence or proliferation of the strain pres-
ent at baseline, pulsed-field gel electrophoresis (PFGE) 
testing was performed for all isolates that were recovered 
at or above threshold at both baseline and any follow-up 
visit.26,27 PFGE gel-banding patterns were captured by a 
digital imaging system, and isolate pairs were classified as 
concordant (closely related), discordant (different strain), 
and indeterminate or nontypeable by standardized criteria. 
Finally, to determine if microbiological failures were due 
to treatment-emergent resistance development, susceptibil-
ity results for any concordant isolate pairs was examined 
further using a $four-fold increase in MIC values for 
besifloxacin or moxifloxacin as indicative of antimicrobial 
resistance development during study treatment.
Table1 Microbiological eradication outcome scale
Category Definition
0 = Eradication Infecting species originally present at or above 
threshold on day 1 is absent in follow-up culture
1 = Reduction Infecting species originally present at or above 
threshold on day 1 is reduced to a count below 
threshold in follow-up culture
2 = Persistence Infecting species originally present at or above 
threshold on day 1 remains present at or above 
threshold in follow-up culture, but does not 
exceed the day 1 count
3 = Proliferation Infecting species originally present at or above 
threshold on day 1 is increased above day 1 
count in follow-up culture
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Results
Study populations
A total of 2393 patients were enrolled across the three studies, 
2387 patients were randomized and treated, and of these 43.6% 
(1041/2387) were culture-confirmed. The integrated rate of 
culture-confirmed patients was consistent with that observed 
in the individual studies (43.9%,16 40.8%,17 and 45.9%18).
Pathogen distribution at baseline
In total, 1324 bacterial isolates were obtained at or above the 
Cagle threshold from the 1041 culture-confirmed patients 
across the three studies. Of these, 49.5% (656/1324), 
22.5% (298/1324), and 27.9% (370/1324) were isolated 
from patients randomized to be treated with besifloxacin 
ophthalmic suspension, vehicle, or moxifloxacin ophthalmic 
solution, respectively. A total of 2.7% (28/1041) of the eyes 
yielding bacterial pathogens at or above threshold also tested 
positive for virus (adenovirus [n = 24] and herpes simplex 
virus [n = 4]).
Table 2 summarizes the baseline pathogens with an 
incidence $ 1% in any one of the treatment groups. The 
most frequently isolated species were Haemophilus influ-
enzae, Streptococcus pneumoniae, Staphylococcus aureus, 
and Staphylococcus epidermidis and were similar across 
all treatment groups and all studies.16–18 Additional species 
isolated, along with an analysis of the differences between 
isolates from US and Asian sites as well as detailed results of 
antimicrobial susceptibility testing at baseline, are presented 
in the companion manuscript by Haas et al.19
Microbiological eradication rates
Overall microbiological eradication rates are presented in 
Figure 1. Visit 2 (day 4 or 5) microbiological eradication 
rates were 92.2%, 91.6%, and 61.4% in eyes treated with 
besifloxacin ophthalmic suspension, moxifloxacin ophthal-
mic solution, and vehicle, respectively; while visit 3 (day 8) 
microbiological eradication rates were 88.4%, 85.7%, and 
72.5%, respectively.
Visit 2 and visit 3 microbiological eradication rates 
for Gram-positive isolates, Gram-negative isolates, and 
for individual species are presented in Table 3. Consistent 
with overall eradication rates, treatment with besifloxacin 
ophthalmic suspension resulted in microbiological eradica-
tion rates that were generally 90% or higher, and that were 
greater than those observed with vehicle treatment and 
similar to those observed with moxifloxacin ophthalmic 
solution. This pattern of microbiological eradication was 
observed for Gram-positive or Gram-negative bacteria and 
by individual species.
Microbiological eradication failures
Table 4 presents microbiological outcomes based on the 
four-point outcome scale along with eradication failures 
imputed due to missing data by treatment and follow-up 
visit. For both active treatment groups, approximately half 
Table 2 Baseline pathogens with incidence $ 1% by treatment group and overall
Organism Treatment group, N (%)
Besifloxacin  
ophthalmic  
suspension, 0.6%
Moxifloxacin  
ophthalmic  
solution, 0.5%
Vehicle Overall
All species 656 (100.0) 370 (100.0) 298 (100.0) 1324 (100.0)
Haemophilus influenzae 167 (25.5) 90 (24.3) 87 (29.2) 344 (26.0)
Streptococcus pneumoniae 153 (23.3) 66 (17.8) 83 (27.9) 302 (22.8)
Staphylococcus aureus 93 (14.2) 56 (15.1) 41 (13.8) 190 (14.4)
Staphylococcus epidermidis 50 (7.6) 41 (11.1) 20 (6.7) 111 (8.4)
Streptococcus mitis groupa 19 (2.9) 14 (3.8) 12 (4.0) 45 (3.4)
CDC coryneform group G 16 (2.4) 11 (3.0) 2 (0.7) 29 (2.2)
Streptococcus mitis 10 (1.5) 5 (1.4) 5 (1.7) 20 (1.5)
Streptococcus oralis 11 (1.7) 4 (1.1) 3 (1.0) 18 (1.4)
Streptococcus spp.a 8 (1.2) 3 (0.8) 2 (0.7) 13 (1.0)
Note: aIsolates that were identified to the species level were listed separately.
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Figure 1 Integrated microbiological eradication rates for isolates from eyes treated 
with besifloxacin ophthalmic suspension, 0.6%, moxifloxacin ophthalmic solution, 
0.5%, or vehicle. Visit 2 took place on day 4 (±1)16 or day 5 (±1)17,18 of study 
treatment; visit 3 took place on day 8 or 9.16–18
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of the microbiological failures were due to persistence of the 
baseline pathogens at the follow-up visits (4.0% and 4.7% for 
besifloxacin, and 3.2% and 5.4% for moxifloxacin at visits 2 
and 3, respectively), and half were due to imputed failures due 
to missing data (2.9% and 5.8% for besifloxacin, and 4.1% 
and 5.9% for moxifloxacin at visits 2 and 3, respectively). 
In contrast, the primary source of microbiological failure in 
the vehicle-treatment group was the observation of persis-
tence/proliferation of baseline pathogens at follow-up visits 
(19.8% and 13.4% for persistence, and 7.7% and 3.0% for 
proliferation at visits 2 and 3, respectively). The distribu-
tion of pathogens in the subset that were not eradicated did 
not differ from that in the subset of eradicated pathogens, 
regardless of treatment group (data not shown). In addition, 
there was no association between microbiological failures 
and co-infection with virus (data not shown).
Figure 2 presents visit 2 microbiological eradication 
results for isolates from besifloxacin-treated eyes from all 
three studies relative to the besifloxacin MIC value for patho-
gens isolated at baseline. Figure 3 presents visit 2 microbio-
logical eradication results for isolates from besifloxacin- and 
moxifloxacin-treated eyes in the active controlled study 
  relative to the besifloxacin and moxifloxacin MIC values, 
respectively, for pathogens isolated at baseline in that study. 
The baseline MIC range for isolates from eyes treated with 
besifloxacin that were eradicated was 0.008–8 µg/mL. The 
MIC range for isolates from eyes treated with besifloxacin 
that resulted in eradication failures (all studies, n = 51; active-
controlled study, n = 22) was 0.015–1 µg/mL, indicating 
that the besifloxacin MIC at baseline was not the primary 
determinant of microbial eradication failures. Minimum 
inhibitory concentration values were higher overall in the 
moxifloxacin treatment group. The baseline MIC range 
for the moxifloxacin-treated isolates was 0.015 to .8 µg/
mL for the isolates that were eradicated (n = 339) and 0.03 
to .8 µg/mL for the isolates that resulted in eradication 
failures (n = 31). However, of the latter, four isolates had 
moxifloxacin MIC values that were $2 µg/mL. Thus, 100% 
(16/16) of isolates from besifloxacin-treated eyes with 
besifloxacin MIC values of 2–8 µg/mL were successfully 
eradicated compared with 87.1% (27/31) of isolates from 
moxifloxacin-treated eyes with moxifloxacin MICs of 2 
to .8 µg/mL. Analysis of visit 3 eradication rates for either 
besifloxacin- or moxifloxacin-treated isolates as a function of 
Table 3 Microbiological eradication of Gram-positive isolates, Gram-negative isolates, and most prevalent species by treatment and visita
Pathogen Treatment, % (n/N)
Besifloxacin ophthalmic  
suspension, 0.6%
Moxifloxacin ophthalmic  
solution, 0.5%
Vehicle
Visit 2 Visit 3 Visit 2 Visit 3 Visit 2 Visit 3
Gram positive 92.2 (412/447) 87.7 (392/447) 89.8 (219/244) 86.5 (211/244) 58.5 (114/195) 71.8 (140/195)
Gram negative 92.3 (193/209) 90.0 (188/209) 95.2 (120/126) 84.1 (106/126) 67.0 (69/103) 73.8 (76/103)
Haemophilus influenzae 91.0 (152/167) 88.6 (148/167) 94.4 (85/90) 87.8 (79/90) 64.4 (56/87) 73.6 (64/87)
Staphylococcus aureus 87.1 (81/93) 83.9 (78/93) 85.7 (48/56) 82.1 (46/56) 39.0 (16/41) 48.8 (20/41)
Staphylococcus epidermidis 94.0 (47/50) 88.0 (44/50) 87.8 (36/41) 78.0 (32/41) 55.0 (11/20) 75.0 (15/20)
Streptococcus pneumoniae 92.8 (142/153) 86.3 (132/153) 90.9 (60/66) 86.4 (57/66) 56.6 (47/83) 73.5 (61/83)
Notes: aVisit 2 took place on day 4 (±1)16 or day 5 (±1)17,18 of study treatment.
Table 4 Microbiological eradication outcomes by treatment and visitsa
Treatment
Success 
Eradicated
n (%)
Imputed failures 
missing data
Observed failures
Reduction Persistence Proliferation
Besifloxacin ophthalmic suspension (N = 656)
Visit 2 605 (92.2) 3 (0.5) 26 (4.0) 3 (0.5) 19 (2.9)
Visit 3 580 (88.4) 1 (0.2) 31 (4.7) 6 (0.9) 38 (5.8)
Moxifloxacin ophthalmic solution (N = 370)
Visit 2 339 (91.6) 3 (0.8) 12 (3.2) 1 (0.3) 15 (4.1)
Visit 3 317 (85.7) 5 (1.4) 20 (5.4) 6 (1.6) 22 (5.9)
Vehicle (N = 298)
Visit 2 183 (61.4) 7 (2.3) 59 (19.8) 23 (7.7) 26 (8.7)
Visit 3 216 (72.5) 4 (1.3) 40 (13.4) 9 (3.0) 29 (9.7)
Note: aVisit 2 took place on day 4 (±1)16 or day 5 (±1)17,18 of study treatment, while visit 3 took place on day 8 or 9.
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baseline MIC resulted in similar findings as those observed 
for visit 2 (data not shown).
PFGE results
Table 5 presents the distribution of bacterial isolate pairs 
with concordant and discordant PFGE results from eyes 
with microbiological eradication failures for both active and 
vehicle treatments. Pulsed field gel electrophoresis banding 
patterns showed that 86.4% (57/66) of isolate pairs from 
besifloxacin-treated eyes and 89.7% (35/39) of isolate pairs 
from moxifloxacin-treated eyes were concordant, indicating 
that the eradication failure was due to the presence of a strain 
that was genetically the same as the strain that was present 
at baseline. In contrast, 12.1% (8/66) and 10.3% (4/39) of 
isolate pairs from besifloxacin- and moxifloxacin-treated 
eyes, respectively, were discordant, indicating that these 
microbiological eradication failures were likely due to new 
infections with different strains of the same species rather 
than reinfection with or persistence of the baseline infecting 
strain. Among vehicle-treated eyes, the percentage of isolate 
pairs determined to be discordant was approximately half that 
observed for the active treatments.
Figure 4 presents the change in MIC relative to base-
line MIC within genetically concordant isolate pairs from 
eyes with microbiological eradication failures following 
active treatment. None of the concordant isolate pairs in 
the besifloxacin or moxifloxacin treatment groups showed 
an increase in MIC for besifloxacin or moxifloxacin that 
was greater than a single twofold dilution, indicating that 
none of the microbiological failures resulted from devel-
opment of fluoroquinolone resistance during the treatment 
period.
Discussion
Besifloxacin is a new fluoroquinolone, specifically a 
  chlorofluoroquinolone, for the topical treatment of bacte-
rial conjunctivitis. Results from three randomized, double-
masked, controlled studies demonstrated the safety and 
efficacy of besifloxacin ophthalmic suspension, 0.6%, 
administered TID for 5 days in patients aged 1–98 years.16–18 
The objectives of this report were to assess the consistency 
of the clinical antimicrobial efficacy of besifloxacin ophthal-
mic suspension, 0.6%, integrated across these three clinical 
studies and to investigate the potential cause(s) for any 
microbiological eradication failures. The current analysis 
includes microbiological eradication data for 1324 bacterial 
pathogens across the three studies.
As expected, the most frequently isolated pathogens   
(H. influenzae, S. pneumoniae, S. aureus, and S. epidermidis) 
were consistent with those isolated in each of the pooled 
studies.16–18 Also, the relative frequencies of each of these 
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at baseline for isolates in the besifloxacin ophthalmic suspension treatment group 
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Figure 3 Visit 2 microbiological eradication versus MIC distribution at baseline in 
the active controlled study. (A) Eradication versus besifloxacin MIC distribution for 
isolates in the besifloxacin ophthalmic suspension treatment group (N = 329). (B) 
Eradication versus moxifloxacin MIC distribution for isolates in the moxifloxacin 
ophthalmic solution treatment group (N = 370). θ = nil.
Abbreviations: MIC, minimum inhibitory concentration; ND, MIC could not be 
determined.
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pathogens were similar to those previously reported in 
patients with bacterial conjunctivitis.1,28 A detailed analysis of 
the causative organisms of bacterial conjunctivitis observed 
in the pooled studies along with their baseline antimicrobial 
susceptibility profiles is provided in the companion paper 
by Haas et al.19
Consistent with the individual study results,16–18 integrated 
microbiological eradication rates with besifloxacin ophthal-
mic suspension were generally 90% or better at visit 2 (day 
4 or 5), attesting to the reproducibility of the clinical micro-
biological eradication data for besifloxacin. Besifloxacin 
treatment resulted in microbiological eradication outcomes 
that were superior to those observed with vehicle treatment 
and similar to those observed with moxifloxacin treatment. 
This was the case for the overall eradication (ie, all isolates) 
for Gram-positive and Gram-negative isolates and individual 
species despite the presence of drug resistance phenotypes at 
baseline (see companion paper by Haas et al).19 In addition, 
100% of the less frequently isolated pathogens from genera 
of ophthalmic interest (Moraxella spp. [n = 8], Neisseria 
spp. [n = 5], Pseudomonas aeruginosa [n = 4], and Serratia 
marcescens [n = 3]) treated with besifloxacin ophthalmic 
suspension were successfully eradicated (data not shown).
There were few microbiological eradication failures 
with either of the active treatments at either of the follow-up 
visits. There was no association between eradication failure 
and any particular bacterial species and/or the presence of 
viral co-infection. Of the failures, approximately half were 
imputed due to missing data, while the majority of the 
observed failures were due to persistence of the baseline 
pathogens at the follow-up visit. Few failures in the active-
treatment groups were due to a reduction in bacterial count 
below the Cagle threshold without complete eradication. As 
expected, the proportion of microbial eradication failures in 
eyes treated with vehicle was higher, as was the percentage 
of eradication failures due to proliferation of the baseline 
pathogen. Visit 3 (days 8 or 9) microbiological eradication 
rates for both of the active treatments were slightly lower 
than those observed at visit 2. These results were consistent 
with the lack of antimicrobial treatment beyond day 5. As 
expected, microbial eradication failures decreased between 
visit 2 and visit 3 in vehicle-treated eyes, presumably due to 
individual host immune factors that characterize this self-
limited disease.
Further investigation showed that microbiological 
eradication failures in the active treatment groups were not 
due to antimicrobial resistance at baseline or antimicrobial 
resistance development during study treatment. There was 
no apparent relationship between microbiological eradica-
tion failures and besifloxacin MIC values for the pathogen 
at baseline in besifloxacin-treated eyes, although the results 
were not as clear for isolates from moxifloxacin-treated eyes. 
In fact, all isolates with MICs $ 2 µg/mL from besifloxacin-
treated eyes were successfully eradicated; whereas11.8% of 
moxifloxacin-treated infections with MICs $ 2 µg/mL were 
not eradicated. The majority of isolate pairs from eyes with 
microbiological failures were determined to be concordant 
based on PFGE banding pattern, and susceptibility data for 
these isolate pairs did not reveal any $ four-fold increases 
in MIC, indicating that there was no development of fluoro-
quinolone resistance during the treatment period.
Most pathogens isolated from patients with bacterial 
conjunctivitis are components of the normal lid and 
nasopharyngeal flora.1,2,27–29 It follows that microbio-
logical eradication failures observed in eyes treated with 
Table 5 Distribution of concordant and discordant isolate pairs from eyes with microbiological eradication failures
Isolate pair Treatment group, n (%)
Besifloxacin ophthalmic  
suspension, 0.6% (N = 66)
Moxifloxacin ophthalmic  
solution, 0.5% (N = 39)
Vehicle (N = 131) Overall (N = 236)
Concordant 57 (86.4) 35 (89.7) 124 (94.7) 216 (91.5)
Discordant 8 (12.1) 4 (10.3) 6 (4.6) 18 (7.6)
Indeterminanta 1 (1.5) 0 (0.0) 1 (0.8) 2 (0.8)
Note: aIndeterminant pulsed-field gel electrophoresis results were obtained for a Streptococcus pneumoniae isolate pair obtained from the besifloxacin treatment group and 
a Streptococcus agalactiae isolate pair obtained from the vehicle treatment group.
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Figure 4 Fold-increase or decrease in MIC relative to baseline for concordant isolate 
pairs from eyes with microbiological eradication failures across the three studies. 
Abbreviation: MIC, minimum inhibitory concentration.
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besifloxacin or moxifloxacin may not be actual eradication 
failures but rather the result of eradication and subsequent 
recolonization/reinfection of eyes with the same strains of 
bacteria present at baseline. It should be noted that the char-
acterization of the majority of observed eradication failures 
being due to persistence of the baseline pathogen does not 
distinguish between true persistence and eradication fol-
lowed by recolonization/reinfection. While recolonization/
reinfection with the baseline pathogen could explain the 
observed eradication failures, especially those additional 
failures observed after treatment termination in the active 
treatment groups, it should be noted that no anti-infective 
studied to date has yielded a 100% microbiological eradica-
tion rate. A recent systematic review of placebo-controlled 
bacterial conjunctivitis studies reported rates from 64.8% to 
94.3% depending on the time of assessment.3 From the data 
presented here, it is clear that the relatively low rate (,10%) 
of microbiological eradication failures in besifloxacin-
treated eyes is not associated with decreased susceptibility 
of the causative bacteria at baseline and/or de novo develop-
ment/acquisition of drug resistance during treatment with 
this topical ophthalmic agent.
A limitation of each study included in this analysis is 
the absence of a nontreatment control. Both besifloxacin 
ophthalmic suspension and its vehicle contain benzalkonium 
chloride (BAK), a quaternary ammonium compound with 
bacteriostatic as well as bactericidal activity,30,31 as a preserva-
tive. BAK could in theory contribute to bacterial eradication 
rates in both the vehicle treatment group and besifloxacin 
treatment group. Without inclusion of a true nontreatment 
control, the full treatment effect of besifloxacin ophthalmic 
suspension cannot be determined.
Conclusion
In summary, besifloxacin ophthalmic suspension, 0.6%, 
administered topically TID for 5 days demonstrated a con-
sistently high rate of clinical microbiological eradication, 
generally 90% or better, for the causative agents of bacterial 
conjunctivitis across three independent, prospective, and 
double-masked bacterial conjunctivitis studies. Microbio-
logical eradication failures were few and were not related 
to fluoroquinolone resistance at baseline and/or resistance 
development during treatment.
Acknowledgment
Species identification, antibacterial susceptibility testing, 
and PFGE analysis was performed by Covance Laboratory 
Services, Inc (Indianapolis, IN).
Disclosure
The authors were employess of Bausch & Lomb during the 
conduct of this analysis.
References
  1.  Høvding G. Acute bacterial conjunctivitis. Acta Ophthalmol. 2008; 
86(1):5–17.
  2.  Diamant JI, Hwang DG. Therapy for bacterial conjunctivitis. 
  Ophthalmol Clin North Am. 1999;12(1):15–20.
  3.  Sheikh A, Hurwitz B. Antibiotics versus placebo for acute bacterial 
conjunctivitis. Cochrane Database Syst Rev. 2006;(2):CD001211.
  4.  Mueller JB, McStay CM. Ocular infection and inflammation. Emerg 
Med Clin North Am. 2008;26(1):57–72.
  5.  Cavuoto K, Zutshi D, Karp CL, Miller D, Feuer W. Update on bacterial 
conjunctivitis in South Florida. Ophthalmology. 2008;115(1):51–56.
  6.  Ward KW, Lepage J-F, Driot J-Y. Nonclinical pharmacodynamics, phar-
macokinetics, and safety of BOL-303224-A, a novel fluoroquinolone 
antimicrobial agent for topical ophthalmic use. J Ocul Pharmacol Ther. 
2007;23(3):243–256.
  7.  Haas W, Pillar CM, Zurenko GE, Lee JC, Brunner LS, Morris TW. 
Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro 
activity against aerobic and anaerobic bacteria. Antimicrob Agents 
Chemother. 2009;53(8):3552–3560.
  8.  Haas W, Pillar CM, Hesje CK, Sanfillippo CM, Morris TW. In vitro 
time-kill experiments with besifloxacin and gatifloxacin in the absence 
and presence of benzalkonium chloride. J Antimicrob Chemother. 2011; 
66(4):840–844.
  9.  Proksch JW, Granvil CP, Siou-Mermet R, Comstock TL, Paterno MR, 
Ward KW. Ocular pharmacokinetics of besifloxacin following topical 
administration to rabbits, monkeys, and humans. J Ocul Pharmacol 
Ther. 2009;25(4):335–343.
  10.  Torkildsen G, Proksch JW, Shapiro A, Lynch SK, Comstock TL. Con-
centrations of besifloxacin, gatifloxacin, and moxifloxacin in human 
conjunctiva after topical ocular administration. Clin Ophthalmol. 2010; 
(4):331–341.
  11.  Carter NJ, Scott LJ. Besifloxacin ophthalmic suspension 0.6%. Drugs. 
2010;70(1):83–97.
  12.  Comstock TL, Karpecki PM, Morris TW, Zhang JZ. Besifloxacin: a 
novel anti-infective for the treatment of bacterial conjunctivitis. Clin 
Ophthalmol. 2010;(4):215–225.
  13.  Chang MH, Fung HB. Besifloxacin: a novel anti-infective for the treat-
ment of bacterial conjunctivitis. Clin Ther. 2010;32(3):454–471.
 14.  Silverstein BE, Allaire C, Bateman KM, Gearinger LS, Morris TW, Com-
stock TL. Efficacy and tolerability of besifloxacin 0.6% ophthalmic suspen-
sion administered twice daily for three days in the treatment of bacterial 
conjunctivitis: a multicenter, double-masked, vehicle controlled, parallel-
group study in adults and children. Clin Ther. 2011; 33(1):13–26.
  15.  Karpecki P, Depaolis M, Hunter JA, et al. Besifloxacin ophthalmic 
suspension 0.6% in patients with bacterial conjunctivitis: a multicenter, 
prospective, randomized, double-masked, vehicle-controlled, 5-day 
efficacy and safety study. Clin Ther. 2009;31(3):514–526.
  16.  Tepedino ME, Heller WH, Usner DW, et al. Phase III efficacy and safety 
study of besifloxacin ophthalmic suspension 0.6% in the treatment of 
bacterial conjunctivitis. Curr Med Res Opin. 2009;25(5):1159–1169.
  17.  McDonald MB, Protzko EE, Brunner LS, et al. Efficacy and safety 
of besifloxacin ophthalmic suspension 0.6% compared with moxi-
floxacin ophthalmic solution, 0.5%, for treating bacterial conjunctivitis. 
  Ophthalmology. 2009;116(9):1615–1623.
  18.  Cagle G, Davis S, Rosenthal A, Smith J. Topical tobramycin and gen-
tamicin sulfate in the treatment of ocular infections: multicenter study. 
Curr Eye Res. 1981;1(9):523–534.
  19.  Hass W, Gearinger LS, Usner DW, DeCory HH, Morris TW. Integrated 
analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic 
suspension, 0.6%: etiology of bacterial conjunctivitis and antibacterial 
susceptibility profile. Clin Ophthalmol. 2011. In press.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1366
Morris et alClinical Ophthalmology
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/clinical-ophthalmology-journal
Clinical Ophthalmology is an international, peer-reviewed journal 
covering all subspecialties within ophthalmology. Key topics include: 
Optometry; Visual science; Pharmacology and drug therapy in eye 
diseases; Basic Sciences; Primary and Secondary eye care; Patient 
Safety and Quality of Care Improvements. This journal is indexed on 
PubMed Central and CAS, and is the official journal of The Society of 
Clinical Ophthalmology (SCO). The manuscript management system 
is completely online and includes a very quick and fair peer-review 
system, which is all easy to use. Visit http://www.dovepress.com/ 
testimonials.php to read real quotes from published authors.
Clinical Ophthalmology 2011:5
  20.  Leibowitz HM. Antibacterial effectiveness of ciprofloxacin 0.3% 
ophthalmic solution in the treatment of bacterial conjunctivitis. Am J 
Ophthalmol. 1991;(112 Suppl 4):29S–33S.
  21.  Clinical and Laboratory Standards Institute. Methods for dilution antimi-
crobial susceptibility tests for bacteria that grow aerobically; approved 
standard – sixth edition. CLSI document M07-A6. Wayne, PA: Clinical 
and Laboratory Standards Institute; 2003.
  22.  Clinical and Laboratory Standards Institute. Methods for dilution antimi-
crobial susceptibility tests for bacteria that grow aerobically; approved 
standard – seventh edition. CLSI document M07-A7. Wayne, PA: 
Clinical and Laboratory Standards Institute; 2006.
  23.  Clinical and Laboratory Standards Institute. Performance standards 
for antimicrobial susceptibility testing; fourteenth informational 
  supplement. CLSI document: M100-S14. Wayne, PA: Clinical and 
Laboratory Standards Institute; 2004.
  24.  Clinical and Laboratory Standards Institute. Performance standards for 
antimicrobial susceptibility testing; sixteenth informational   supplement. 
CLSI document M100-S16. Wayne, PA: Clinical and Laboratory 
Standards Institute; 2006.
  25.  Ichiyama S, Ohta M, Shimokata K, Kato N, Takeuchi J. Genomic DNA 
fingerprinting by pulsed-field gel electrophoresis as an epidemiological 
marker for study of nosocomial infections caused by methicillin-resistant 
Staphylococcus aureus. J Clin Microbiol. 1991;29(12):2690–2695.
  26.  Tenover FC, Arbeit RD, Goering RV , et al. Interpreting chromosomal 
DNA restriction patterns produced by pulsed-field gel electrophore-
sis: criteria for bacterial strain typing. J Clin Microbiol. 1995;33(9): 
2233–2239.
  27.  Tarabishy AB, Jeng BH. Bacterial conjunctivitis: a review for internists. 
Cleve Clin J Med. 2008;75(7):507–512.
  28.  Gigliotti F, Williams WT, Hayden FG, et al. Etiology of acute conjunc-
tivitis in children. J Pediatr. 1981;98(4):531–536.
  29.  Brook I, Pettit TH, Martin WJ, Finegold SM. Anaerobic and aerobic 
bacteriology of acute conjunctivitis. Ann Ophthalmol. 1979;11(3): 
389–393.
  30.  McDonnell G, Russell AD. Antiseptics and disinfectants: activity, action 
and resistance. Clin Microb Rev. 1999:12(1):147–179.
  31.  Blondeau JM, Boros S, Hesje CK. Antimicrobial efficacy of gatifloxacin 
and moxifloxacin with and without benzalkonium chloride compared 
with ciprofloxacin and levofloxacin against methicillin-resistant Staphy-
lococcus aureus. J Chemother. 2007;19(2):146–151.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
1367
Microbiological eradication outcomes in besifloxacin clinical studies